Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Universitaire Ziekenhuizen Leuven RITA Medical Systems B. Braun Medical SA |
---|---|
Information provided by: | Universitaire Ziekenhuizen Leuven |
ClinicalTrials.gov Identifier: | NCT00484848 |
Totally implanted venous access ports allow a safe delivery of medication, mainly chemotherapy, but are also used for blood sampling. This last procedure is not always successful, as it appeared from a nurse’s survey in different hospitals in Flanders, including the University Hospitals in Leuven, Belgium. In 3 to 29 percent of the attempts, blood withdrawal is impaired or not possible, as an intermittent or permanent fact. This is in line with international literature data where difficulty in blood draw was noted in 6 to 26% of port accessions. Partial or total occlusion leads to discomfort for the patient, delay in therapy, higher costs and extra nursing time.
A new port system with a tangential outlet (Vortex port) was designed and according to the manufacturer, this shape will allow to cleanse the entire reservoir of the port more efficiently and avoid the formation of precipitates of medication or blood that could lead to an obstruction of the device. These precipitates are also regarded as a potential risk factor for infection.
However, only one previously published small randomised study addressed the value of the Vortex port when compared to conventional access devices: Stevens et al. were able to show a reduction in obstruction incidence from 26% to 7% with the use of the Vortex port. The incidence of blood withdrawal problems in our experience with conventional ports in University hospitals Leuven was 8% thus lower than that reported by Stevens, but this remains the most frequent problem faced by care providers and patients.
With this study, we aim to compare the performance of the tangential outlet ports and that of a “conventional” port in order to assess an eventual functional difference.
Condition | Intervention |
---|---|
Oncology, Medical Hematologic Disease |
Device: Vortex port and Celsite port |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Functional Evaluation of Conventional Venous Access Port (Celsite®) Versus Venous Access Port With Tangential Outlet (Vortex®) : a Prospective Randomized Pilot Study |
Enrollment: | 200 |
Study Start Date: | September 2004 |
Study Completion Date: | March 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Belgium | |
University Hospitals Leuven | |
Leuven, Belgium, 3000 |
Principal Investigator: | Marguerite Stas, MD PhD | Katholieke Universiteit Leuven |
Study ID Numbers: | SM007 |
Study First Received: | June 7, 2007 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00484848 |
Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products |
implantable catheter vascular access ports persistent withdrawal occlusion Vortex® |
Celsite® Vacutainer® venous cut-down |
Hematologic Diseases |